Literature DB >> 33826598

Panel-reactive Antibody and the Association of Early Steroid Withdrawal With Kidney Transplant Outcomes.

Sunjae Bae1,2,3, Mara A McAdams-DeMarco1,2, Allan B Massie1,2, Jacqueline M Garonzik-Wang1, Josef Coresh2,3,4, Dorry L Segev1,2.   

Abstract

BACKGROUND: Early steroid withdrawal (ESW) is a viable maintenance immunosuppression strategy in low-risk kidney transplant recipients. A low panel-reactive antibody (PRA) may indicate low-risk condition amenable to ESW. We aimed to identify the threshold value of PRA above which ESW may pose additional risk and to compare the association of ESW with transplant outcomes across PRA strata.
METHODS: We studied 121 699 deceased-donor kidney-only recipients in 2002-2017 from Scientific Registry of Transplant Recipients. Using natural splines and ESW-PRA interaction terms, we explored how the associations of ESW with transplant outcomes change with increasing PRA values and identified a threshold value for PRA. Then, we assessed whether PRA exceeding the threshold modified the associations of ESW with 1-y acute rejection, death-censored graft failure, and death.
RESULTS: The association of ESW with acute rejection exacerbated rapidly when PRA exceeded 60. Among PRA ≤60 recipients, ESW was associated with a minor increase in rejection (adjusted odds ratio [aOR], 1.001.051.10) and with a tendency of decreased graft failure (adjusted hazard ratio [aHR], 0.910.971.03). However, among PRA >60 recipients, ESW was associated with a substantial increase in rejection (aOR, 1.191.271.36; interaction P < 0.001) and with a tendency of increased graft failure (aHR, 0.981.081.20; interaction P = 0.028). The association of ESW with death was similar between PRA strata (PRA ≤60, aHR, 0.910.961.01; and PRA >60, aHR, 0.900.991.09; interaction P = 0.5).
CONCLUSIONS: Our findings show that the association of ESW with transplant outcomes is less favorable in recipients with higher PRA, especially those with PRA >60, suggesting a possible role of PRA in the risk assessment for ESW.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 33826598      PMCID: PMC8490476          DOI: 10.1097/TP.0000000000003777

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   5.385


  41 in total

1.  Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years.

Authors:  Mysore S Anil Kumar; Michael Heifets; Michael J Moritz; Muhammad I Saeed; Shahid M Khan; Billie Fyfe; Nedjema Sustento-Riodeca; Joshua N Daniel; Aparna Kumar
Journal:  Transplantation       Date:  2006-03-27       Impact factor: 4.939

2.  Revisiting traditional risk factors for rejection and graft loss after kidney transplantation.

Authors:  T B Dunn; H Noreen; K Gillingham; D Maurer; O G Ozturk; T L Pruett; R A Bray; H M Gebel; A J Matas
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

3.  Effective communication of standard errors and confidence intervals.

Authors:  Thomas A Louis; Scott L Zeger
Journal:  Biostatistics       Date:  2008-06-10       Impact factor: 5.899

4.  The implications of acute rejection for allograft survival in contemporary U.S. kidney transplantation.

Authors:  Krista L Lentine; Adrian Gheorghian; David Axelrod; Anu Kalsekar; Gilbert L'italien; Mark A Schnitzler
Journal:  Transplantation       Date:  2012-08-27       Impact factor: 4.939

5.  Early Steroid Withdrawal in Deceased-Donor Kidney Transplant Recipients with Delayed Graft Function.

Authors:  Sunjae Bae; Jacqueline M Garonzik Wang; Allan B Massie; Kyle R Jackson; Mara A McAdams-DeMarco; Daniel C Brennan; Krista L Lentine; Josef Coresh; Dorry L Segev
Journal:  J Am Soc Nephrol       Date:  2019-12-18       Impact factor: 10.121

6.  The antibody crossmatch in liver transplantation.

Authors:  R D Gordon; J J Fung; B Markus; I Fox; S Iwatsuki; C O Esquivel; A Tzakis; S Todo; T E Starzl
Journal:  Surgery       Date:  1986-10       Impact factor: 3.982

7.  Long-term immunosuppression, without maintenance prednisone, after kidney transplantation.

Authors:  Arthur J Matas; Raja Kandaswamy; Abhinav Humar; William D Payne; David L Dunn; John S Najarian; Rainer W G Gruessner; Kristen J Gillingham; Lois E McHugh; David E R Sutherland
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

8.  A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.

Authors:  Giuseppe Montagnino; Silvio Sandrini; Beniamino Iorio; Francesco Paolo Schena; Mario Carmellini; Paolo Rigotti; Maria Cossu; Paolo Altieri; Maurizio Salvadori; Sergio Stefoni; Giuseppe Corbetta; Claudio Ponticelli
Journal:  Nephrol Dial Transplant       Date:  2007-09-21       Impact factor: 5.992

9.  Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.

Authors:  Bernhard K Krämer; Marian Klinger; Štefan Vítko; Maciej Glyda; Karsten Midtvedt; Sergio Stefoni; Franco Citterio; Frank Pietruck; Jean-Paul Squifflet; Giuseppe Segoloni; Bernd Krüger; Heide Sperschneider; Bernhard Banas; Lars Bäckman; Markus Weber; Mario Carmellini; Ferenc Perner; Kerstin Claesson; Wojciech Marcinkowski; Marek Ostrowski; Grzegorz Senatorski; Johan Nordström; Kaija Salmela
Journal:  Transplantation       Date:  2012-09-15       Impact factor: 4.939

Review 10.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.

Authors:  Peter C Austin; Elizabeth A Stuart
Journal:  Stat Med       Date:  2015-08-03       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.